Graphite Bio, Inc.: directors' dealings · United States · SEC (Form 4)

About Graphite Bio, Inc.

Graphite Bio, Inc. was a U.S.-based biotechnology company focused on next-generation gene editing and genetic medicines. The company was built around a targeted gene integration platform developed from Stanford-linked scientific work, with an early mission centered on potentially curative, one-time treatments for serious inherited diseases. Graphite Bio was originally incorporated in 2017 as Longbow Therapeutics, later reincorporated in Delaware, and ultimately became Graphite Bio, Inc. Its headquarters were in South San Francisco, California, placing it in one of the most important biotech clusters in the United States. Graphite Bio’s common stock traded on the Nasdaq Global Market under the symbol GRPH, making it a U.S.-listed biotech name followed by investors focused on high-risk, high-potential therapeutic innovation. From a market context standpoint, the key point is that Graphite Bio no longer operates as an independent listed company: on March 21, 2024, it completed a merger with LENZ Therapeutics, and the surviving entity adopted the LENZ Therapeutics, Inc. name. As a result, any discussion of Graphite Bio today is primarily historical and should be understood in the context of the former public company and the post-merger corporate structure. From a business perspective, Graphite Bio was a clinical-stage gene editing company aiming to harness precise gene correction to treat or cure severe diseases. Its technology was designed to enable targeted gene integration, an approach intended to improve on earlier gene-editing concepts by aiming for more accurate genomic repair. The company’s best-known historical program was nulabeglogene autogedtemcel, or nula-cel, a sickle cell disease candidate. In February 2023, Graphite Bio announced that it would discontinue further development of nula-cel and begin exploring strategic alternatives. That decision was a major inflection point: it reduced near-term clinical optionality and highlighted the scientific, regulatory, and execution risks common in advanced gene-editing development. Graphite Bio also indicated it would continue early-stage work on a non-genotoxic conditioning program, but the later merger with LENZ effectively reset the company’s strategic direction. Competitive positioning in this space was challenging. Graphite Bio operated in a field populated by well-capitalized gene-editing and cell-therapy peers, where intellectual property, translational data, manufacturing capability, and clinical execution are all decisive. Its geographic footprint was concentrated in the United States, with operations and leadership centered in California and scientific visibility extending into the broader global biotech ecosystem. For French-speaking investors, Graphite Bio is best viewed as a case study in frontier biotechnology: strong scientific ambition, meaningful platform differentiation, high development risk, and a corporate outcome shaped by strategic restructuring rather than standalone commercialization.